Discovery Life Sciences Acquires AllCells
July 12, 2022
Discovery Life Sciences™ (Discovery), the biospecimen and biomarker specialists™, today announced its acquisition of AllCells® , a leading provider of clinical-grade (GMP-compliant) and Research Use Only (RUO) primary cell products. With more than ...
Read More
Discovery Life Sciences’ HudsonAlpha Discovery Becomes One of the World’s Largest PacBio HiFi Sequencing Service Providers
ESTABLISHES A SINGULAR, LARGE-SCALE HIFI LONG READ SEQUENCING SERVICE FOR THE BIOPHARMACEUTICAL INDUSTRY
June 7, 2022
Read MoreDiscovery Life Sciences To Acquire Gentest Business From Corning Incorporated
May 2, 2022
Biospecimen Leader to Combine Gentest with Recent IVAL Acquisition to Create Leading In Vitro Drug Metabolism Services Offering
Read More
Seer, Discovery Life Sciences and SCIEX Announce First-Of-Its-Kind Proteogenomics Consortium for Large-Scale Studies
January 10, 2022
Delivery of 100,000 Samples of Capacity Annually to the Market, Empowering Genomics Researchers to Add Deep, Unbiased Proteomics Analysis to their Studies
Read More
Discovery Life Sciences Acquires In Vitro ADMET Laboratories
December 2, 2021
Biospecimen Leader Gains World’s Largest Hepatocyte Inventory And World-Renowned Scientific Leader With Latest Acquisition
Read More
Discovery Life Sciences Launches TruSight Oncology 500 (TSO500) Solid Tumor FFPE and cfDNA Services to Advance Liquid Biopsy Development and Immunotherapy Clinical Research
November 12, 2021
HUNTSVILLE, Ala., Nov. 12, 2020, Discovery Life Sciences™ (Discovery), a global leader in biospecimen solutions, genomic, cell, and immunohistochemistry (IHC) services, announces the addition of Illumina’s TruSight Oncology 500 (TSO500) technology ...
Read More
To propel your projects with The Power of Discovery.™
Contact Us Today
Let us know about your project!
